Blood test may spot lung cancer mutations faster

NCT ID NCT04912687

Completed Diagnosis Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a simple blood test (liquid biopsy) can detect EGFR gene mutations in people with advanced non-small cell lung cancer. Researchers collected blood samples from 581 patients and compared the results with standard tissue testing. The goal was to see if adding the blood test helps find more patients who could benefit from targeted therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this approach could make it easier and faster to detect treatable genetic mutations in lung cancer, helping doctors choose the right treatment sooner.
What could go wrong: This is an observational study, not a treatment trial. It only tests a diagnostic method, so it won't directly improve outcomes. The blood test may miss some mutations found in tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

CHRU Lille

Lille, 59037, France
CHU Nice-Hopital de Cimiel

Nice, 06000, France
CHU Poitiers

Poitiers, 86021, France
CHU Strasbourg

Strasbourg, 67091, France
CHU de Rennes - Hopital Pontchaillou

Rennes, 35033, France
Hospices Civils de Lyon

Lyon, 69002, France
Institut Bergonie

Bordeaux, 33076, France
Institut Curie

Paris, 75248, France
Institut de Cancérologie de l'Ouest - Site Paul Papin

Angers, 49000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.